공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 식도암 시장(2021-2028년)

Global Esophageal Cancer Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1008253
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,209,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,807,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,400,000 PDF & Excel (Enterprise License)


세계의 식도암 시장(2021-2028년) Global Esophageal Cancer Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

식도암은 식도 조직에 암세포가 생기는 질환으로, 흡연, 과도한 음주 등이 위험인자가 되고 있습니다. 식도암 증상에는 체중 감소, 삼킴시 통증이나 트러블이 있습니다. 세계의 식도암 시장은 치료법 연구개발 활발화, 신제품 발매 등에 의해 성장이 촉진될 전망입니다.

세계의 식도암(Esophageal Cancer) 시장을 조사했으며, 시장 개요, 부문·지역별 시장 규모 및 성장률 추정과 예측, 신종 코로나바이러스 감염증(COVID-19)의 영향 분석, 시장 성장 촉진요인 및 억제요인 분석, 시장 기회, 가격 및 무역 동향, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

목차

제1장 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 시장 정의와 개요

제3장 주요 요약

  • 시장 내역 : 종류별
  • 시장 내역 : 치료법별
  • 시장 내역 : 투여 경로별
  • 시장 내역 : 최종사용자별
  • 시장 내역 : 지역별

제4장 시장 역학

  • 시장 영향요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 업계 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 상환 분석
  • 미충족 수요

제6장 신종 코로나바이러스 감염증(COVID-19)의 영향 분석

  • 신종 코로나바이러스 감염증(COVID-19)의 영향 분석
    • 코로나 이전 시장 시나리오
    • 현재 시장 시나리오
    • 코로나 이후 시장 시나리오
  • 코로나 동안 가격 동향
  • 수급 스펙트럼
  • 코로나 동안 시장에 대한 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 식도암 시장 : 종류별

  • 서론
  • 시장 규모·전년대비 성장률 분석 : 종류별
  • 시장 매력 지수 : 종류별
    • 선암
    • 성상장간질종양
    • 카르시노이드종양
    • 편평상피암
    • 기타

제8장 세계의 식도암 시장 : 치료법별

  • 서론
  • 시장 규모·전년대비 성장률 분석 : 치료법별
  • 시장 매력 지수 : 치료법별
    • 표적요법
    • 면역요법
    • 화학요법

제9장 세계의 식도암 시장 : 투여 경로별

  • 서론
  • 시장 규모·전년대비 성장률 분석 : 투여 경로별
  • 시장 매력 지수 : 투여 경로별
    • 경구
    • 비경구
    • 기타

제10장 세계의 식도암 시장 : 최종사용자별

  • 서론
  • 시장 규모·전년대비 성장률 분석 : 최종사용자별
  • 시장 매력 지수 : 최종사용자별
    • 병원
    • 진료소
    • 외래 외과 센터

제11장 세계의 식도암 시장 : 지역별

  • 서론
    • 시장 규모 분석·전년대비 성장률 : 지역별
    • 시장 매력 지수 : 지역별
  • 북미
    • 서론
    • 시장 역학
    • 시장 규모·전년대비 성장률 : 종류별
    • 시장 규모·전년대비 성장률 : 치료별
    • 시장 규모·전년대비 성장률 : 투여 경로별
    • 시장 규모·전년대비 성장률 : 최종사용자별
    • 시장 규모·전년대비 성장률 : 국가별
  • 유럽
    • 서론
    • 시장 역학
    • 시장 규모·전년대비 성장률 : 종류별
    • 시장 규모·전년대비 성장률 : 치료별
    • 시장 규모·전년대비 성장률 : 투여 경로별
    • 시장 규모·전년대비 성장률 : 최종사용자별
    • 시장 규모·전년대비 성장률 : 국가별
  • 남미
    • 서론
    • 시장 역학
    • 시장 규모·전년대비 성장률 : 종류별
    • 시장 규모·전년대비 성장률 : 치료별
    • 시장 규모·전년대비 성장률 : 투여 경로별
    • 시장 규모·전년대비 성장률 : 최종사용자별
    • 시장 규모·전년대비 성장률 : 국가별
  • 아시아태평양
    • 서론
    • 시장 역학
    • 시장 규모·전년대비 성장률 : 종류별
    • 시장 규모·전년대비 성장률 : 치료별
    • 시장 규모·전년대비 성장률 : 투여 경로별
    • 시장 규모·전년대비 성장률 : 최종사용자별
    • 시장 규모·전년대비 성장률 : 국가별
  • 중동 및 아프리카
    • 서론
    • 시장 역학
    • 시장 규모·전년대비 성장률 : 종류별
    • 시장 규모·전년대비 성장률 : 치료별
    • 시장 규모·전년대비 성장률 : 투여 경로별
    • 시장 규모·전년대비 성장률 : 최종사용자별

제12장 경쟁 상황

  • 경쟁 시나리오
  • 시장 포지셔닝/점유율 분석
  • 인수합병 분석

제13장 기업 개요

  • Amgen Inc.
    • 기업 개요
    • 제품 포트폴리오
    • 주요 하이라이트
    • 재무 상황
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences
  • Genentech Inc.

제14장 주요 인사이트

제15장 DataM Intelligence 소개

KSM 21.06.29

Market Overview

The global esophageal cancer market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Esophageal cancer is a condition in which cancer cells form in the tissues of the esophagus. Smoking, excess alcohol, and Barrett's esophagus can raise the risk of esophageal cancer. Signs and indications of esophageal cancer are weight loss and pain or trouble in swallowing. This cancer starts on the interior lining of the esophagus and flows outward within the other layers as it progresses. At succeeding stages, esophageal cancer can be treated but infrequently can be cured.

Market Dynamics

The esophageal cancer market growth is driven by the the rise in cases of esophageal cancer which creates an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and adoption of sedentary life-style are some of the impacting factors for the demand of esophageal cancer drugs.

Increasing research and development for the treatment of esophageal cancer will drive the market growth

Rising research and development and launches of novel products by key players are significant constituents is expected to drive the growth of the global esophageal cancer market in the forecast period. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to drive the growth of esophageal cancer drug market size significantly.

For instance, in February 2019, researchers at Case Western Reserve University discovered that blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma, the most common esophageal malignancy the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.

Government of several economies and various non-government organizations are taking initiatives to increase patient awareness about esophageal cancer. Research related to esophageal cancer has recently caught the consideration of oncologists and experts. The enormous scale of disease types associated with esophageal cancer is behind the revitalized interest of the medical fraternity. Moreover, increased consumption of carcinogens existing in specific foods has also become a concern for oncologists. Therefore, the growth of the global esophageal cancer market mainly hinges on the efforts taken by the medical organization to alleviate the occurrence of esophageal cancer.

The prevalence of achalasia is expected to drive the esophageal cancer market growth

The significant risk factors that lead to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors will increase the demand for esophageal cancer drugs over the forecast period. For instance, according to a study published in National Center for Biotechnology Information in 2017, achalasia patients have a 50 times more prominent risk of esophageal squamous cell carcinoma than the general population. The overall predominance of achalasia is 9 to 10 in 100,000 people annually worldwide.

The rising prevalence of disorders like adenocarcinoma and squamous cell carcinoma in the US also contributes to the market's growth in the forecast period. In addition, the consecutive occurrence of GERD causes dysplasia, eventually resulting in uncontrolled growth of cells in the esophagus. This factor will further increase the esophageal cancer market in the forecast period.

Side effects associated with certain medications coupled with high cost of cancer treatment

The side effects begun by esophageal cancer drugs are loss of hunger and weight loss, weakness, diarrhea, sore mouth, hair loss, low blood cell counts, hand-foot syndrome, blood clots (deep vein thrombosis), heart damage and nervous system damage. According to the report published in the American Cancer Society (ACS) in 2017, the side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause significant damage to nerves outside the brain and spinal cord.

The high cost of the therapy in the treatment of esophageal cancer will hamper the market growth in the forecast period. For instance, according to the report published by HealthDay, cancer patients paid US$ 207,000 per year for their treatment and medicines, while in 1995, the cost was US$ 54,100 per year.

COVID-19 Impact Analysis

Reports suggest a higher risk of COVID-19 infection with associated severe morbidity and mortality in cancer patients. The complexity of the multidisciplinary approach to esophageal cancer patients and the high morbidity rates of esophageal surgery has challenged the treatment pathways of these patients.

According to Oxford Academics, the surgery of patients who have cancer was limited in 24 (36.9%) patients in 6 (50%) centers, mostly due to deficiency of anesthesiologists and occupation of intensive care unit beds from intubated COVID-19 patients. Implications for neoadjuvant chemo (radio) therapy were increased in 14% of patients. Separate COVID-19 hospital pathways were active in 11 (91.7%) units. COVID-19 screening protocols covered nasopharyngeal swab in 91.7%, chest computed tomography scan in 8.3% and particular use of lung ultrasound in 75% of units. Postoperative interstitial pneumonia occurred in 1 (1.5%) patient.

Segment Analysis

Gastrointestinal stromal tumors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Gastrointestinal stromal tumors (GISTs) are unusual cancers that arise in specific cells on the surface of the gastrointestinal (GI) tract, and it is also known as the digestive tract. The GI tract prepares food for energy and rids the body of fixed waste.

The food and gastric juices are then discharged into the small intestine. The small intestine continues busting down the food and absorbs most of the nutrients into the bloodstream. Some GISTs seem to be much more likely than others to grow into other areas or spread to other parts of the body.

GISTs Cancers can occur anywhere in the GI tract, from the throat to the anus. Most cancers that start in the GI tract, including most esophagus cancers, stomach cancers, and colon and rectum cancers, start in the gland cells that line almost all GI tracts. The malignancies that develop in these cells are called adenocarcinomas.

The GI tract also has neuroendocrine cells. These cells have some features in common with nerve cells but also have other features in common with hormone-producing (endocrine) cells. Cancers that develop from these cells are called neuroendocrine tumors (NETs). These cancers are rare in the GI tract. Carcinoid tumors are an example of a neuroendocrine tumor found in the GI tract.

The chemotherapy segment are expected to dominate the esophageal cancer market during the forecast period

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Geographical Analysis

North America region holds the largest market share global Esophageal Cancer Market

North America region is dominating the esophageal cancer market accounted for the largest market share in 2020, owing to the growing prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society's report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.

Numerous cancer research institutes and Universities have linked their synergies to develop a stable method for treating melanoma. Case Western Reserve University in the United States, in the initial quarter of 2019, developed a pathway that can restrain the occurrence of esophageal cancer. The research was based on testimony collected from an extended series of examinations. Such advancements are expected to develop the possibilities of growth in the esophageal cancer market in the region.

Competitive Landscape

The esophageal cancer market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, Bristol-Myers Squibb Company, and Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Sanofi-Aventis Merck & Co. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the esophageal cancer market globally.

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Why Purchase the Report?

  • Visualize the composition of the esophageal cancer market segmentation by type, therapy and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in esophageal cancer market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of esophageal cancer market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global esophageal cancer market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Esophageal Cancer Market - By Type

  • Adenocarcinomas
  • Astrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Other

Global Esophageal Cancer Market- By Therapy

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Global Esophageal Cancer Market - By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Global Esophageal Cancer Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global Esophageal Cancer Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Esophageal Cancer Market - Market Definition and Overview

3. Global Esophageal Cancer Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Therapy
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Esophageal Cancer Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing research and development for the treatment of cancer will drive the market growth
      • 4.1.1.2. The prevalence of achalasia is expected to drive growth of the esophageal cancer market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. Side Effects associated with Certain Medications Coupled with High Cost of Cancer treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Esophageal Cancer Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Esophageal Cancer Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Esophageal Cancer Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Adenocarcinomas*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Astrointestinal Stromal Tumors
  • 7.4. Carcinoid Tumors
  • 7.5. Squamous Cell Carcinoma
  • 7.6. Other

8. Global Esophageal Cancer Market - By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 8.1.2. Market Attractiveness Index, By Therapy
  • 8.2. Targeted Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Immunotherapy
  • 8.4. Chemotherapy

9. Global Esophageal Cancer Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers

10. Global Esophageal Cancer Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Esophageal Cancer Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Esophageal Cancer Market- Company Profiles

  • 12.1. Amgen Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Eli Lilly and Company
  • 12.3. Hoffmann-La Roche
  • 12.4. Bristol-Myers Squibb Company
  • 12.5. Boehringer Ingelheim GmbH
  • 12.6. GlaxoSmithKline Plc.
  • 12.7. Novartis AG
  • 12.8. Johnson & Johnson
  • 12.9. Gilead Sciences

LIST NOT EXHAUSTIVE

13. Global Esophageal Cancer Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q